Actively Recruiting

All Genders
NCT07019038

National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17

9999

Participants Needed

1

Research Sites

3652 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of autoimmune hemolytic anemia (AIHA) and to analyze the treatment effectiveness, patient prognosis and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with AIHA, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of AIHA patients, such as biochemical and hematological indicators 3. Assess treatment patterns and real-world effectiveness in AIHA patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.

CONDITIONS

Official Title

National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with autoimmune hemolytic anemia (AIHA)
  • Hemoglobin level less than 100 g/L
  • Treated at the Institute of Hematology and Blood Diseases Hospital from January 1, 2001 onward
Not Eligible

You will not qualify if you...

  • Unable to participate in long-term follow-up for any reason, such as difficulty obtaining follow-up data or severe other illnesses
  • Alcohol or drug dependence that may affect study compliance
  • Any other reasons judged by investigators that make the participant unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Red Blood Cell Diseases Center and Regenerative Medicine Center

Tianjin, Tianjin Municipality, China

Actively Recruiting

Loading map...

Research Team

L

Lele Zhang, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here